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Abstract
Background: Vitamin D (D) supplements are indispensable for its world-wide deficiency. Controversy continues on
ergocalciferol (D2) and cholecalciferol (D3) relative potency as well as on dosing-schedule and sex role in raising
25-hydroxy D (25(OH)D) level, the best indicator of D status.
Methods: We randomized 279 adults to daily D2, D3, D2/D3, or placebo; 2-weekly D2 or D3; or 4-weekly D2 or D3
(250,000 IU over/140 days). Randomization sequence, stratified by body-mass-index (BMI) and sex, was concealed
from study coordinators and participants who were then blinded to capsules’ content. D2, D3, 25(OH)D2, and
25(OH)D3 Serum levels were determined blindly on days 0,1,2,3,4,7,14, and 2-weekly thereafter by high performance
liquid chromatography assay. The results of 269 participants were available for analysis. Primary endpoint was area-
under-the-curve (AUC) of 25(OH)D (25(OH)D2 + 25(OH)D3) adjusted for sex, BMI, and baseline 25(OH)D level.
Results: Mean(SD) age was 33.0(8.5) year, 41% were males, and 85% completed follow-up. Baseline 25(OH)D level
was 39.8(11.9) and increased by 3.3(11.6) and 28.6(16.3) nmol/L, in the placebo and active-treatment groups,
respectively. AUC from day 0 to 140 (AUC140) of 25(OH)D was 40% (D3 daily) to 55% (D3 2-weekly) higher with
active-treatment than placebo (p < 0.001). 25(OH)D2 AUC140 was higher in daily than 2-weekly (17%, p = 0.006) and
4-weekly (20%, p = 0.001) D2-treated groups. 25(OH)D3 AUC140 was lower in daily than 2-weekly (11%, p = 0.002)
and 4-weekly D3-treated groups (10%, p = 0.008). In D2-treated groups, there was 16.4 nmol/L decrease in 25(OH)
D3 level that correlated (p < 0.001) with 25(OH)D2 level increase (r = 0.48) and baseline 25(OH)D level (r = 0.58), in
one participant with measurable baseline 25(OH)D2 level, D3 caused a similar decrease in 25(OH)D2 level, while in
the D2/D3-treated group, 25(OH)D3 level didn’t increase. Incremental AUC from day 0 to 7 (AUC7) of D3 and
25(OH)D3 in D3-treated groups were 118–243% higher and 31–39% lower, respectively, than incremental AUC7 of
D2 and 25(OH)D2 in D2-treated groups. Incremental AUC7 of D3 and 25(OH)D3 in D3-treated groups and D2 and
25(OH)D2 in D2-treated groups were higher in females than males (55, 13, 64, and 28%, respectively). Baseline
25(OH)D level predicted response to D2 and D3 (p < 0.001), whereas, BMI was significant predictor only for early
response to D2.
Conclusions: Effects of D2 and D3 supplements on 25 (OH)D level may be dosing-schedule and sex-dependent.
D2-associated reduction in 25(OH)D3 level may be related to total 25(OH)D level rather than being D2-specific. D2
may be 25-hydroxylated faster than D3.
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Background
The increasingly recognized effects of vitamin D (D) on
skeletal and extra-skeletal tissues [1, 2] together with
worldwide D deficiency have amplified attention to D
supplementation. Nevertheless, the relative potency of
ergocalciferol (D2) vs cholcalciferol (D3), and the prefer-
able dosing strategy continue to be controversial [3].
The same unit is used for both D2 and D3, suggesting
biological equivalence in terms of raising serum total 25-
hydroxy D (25(OH)D) level, [4] the best current bio-
marker of D status. However, published studies have
yielded mixed results [4–13]. This may be due in part to
the facts that supplement-induced increase in 25(OH)D
level may be related to baseline level, [9, 11, 13–16] body
mass index (BMI), [12–14, 16–21] sex, [13, 22, 23] dos-
ing strategy, [24] meal content, [25] and duration of fol-
low up, which have not been systematically controlled
for. A meta-analysis found that D3 is significantly more
potent than D2 as bolus dosing but not as daily dosing
[24]. Further, the dose–response curve may be curvilin-
ear rather than linear [13, 20, 21, 26, 27].
D2 and D3 differ in their side chain structure, conver-
sion to 25(OH)D by hepatic 25-hydroxylase, affinity (and
affinity of their metabolites) to circulating D binding pro-
tein, inactivation by 24-hydroxylation, and plasma half-life
[24, 28]. However, in respect to binding to D receptor, the
active dihydroxyvitamin D forms, 1,25(OH)2D2 and
1,25(OH)2D3, appear to be comparable [1]. Further,
25(OH)D2 and 25(OH)D3 appear to be equally recognized
by the kidney 1-alpha hydroxylase [29–31].
Equivalent oral doses of D given daily compared to
less frequently may result in differing increments in
25(OH)D [32] and D [2] levels. Circulating D has better
general cellular accessibility than 25(OH)D due to its
lower affinity to circulating D binding protein and may
play an important physiological role as a substrate for
many tissues [2].
It has been noticed that D2 supplementation is associ-
ated with reduction in 25(OH)D3 [5, 8, 33–35] and
1,25(OH)2D3 [36] levels. The underlying mechanism has
not been elucidated; it is possible that the reduction is
not specific to D2 supplementation and merely reflects a
response to increasing 25(OH)D levels.
The primary aim of this study was to systematically
evaluate the relative efficacy of various dosing strategies of
D2 and D3 oral supplements in raising 25(OH)D levels.
Methods
Design
The study was randomized, placebo-controlled, partially
blinded trial to compare the effect of seven D oral regi-
mens on 25(OH)D level. Participants were randomly al-
located to daily D2, D3, combination of D2 and D3, or
placebo; 2-weekly D2 or D3; or 4-weekly D2 or D3.
Total D dose in the active treatment groups was
250,000 IU over 140 days.
Participants
Volunteers were recruited via advertisement throughout
the King Faisal Specialist Hospital and Research Center
(KFSH&RC) and other medical centers in the City of
Riyadh, Saudi Arabia. We enrolled healthy non-pregnant
adults (age 18–60 years) living in Riyadh area who don’t
consume more than one serving of milk daily, don’t take
vitamin supplements, habitually have less than 10 h of sun
exposure weekly, don’t suffer from granulomatous, liver,
or kidney diseases, don’t take anticonvulsants, barbitu-
rates, or steroids, and have 25(OH)D level between 20 and
50 nmol/L. Potential participants were screened by obtain-
ing medical history and the following tests: complete
blood count, serum creatinine, calcium, phosphorous, al-
bumin, bilirubin, and alanine aminotransferase, and spot
urine calcium, phosphate, and creatinine. The study was
conducted at KFSH&RC from February 2013 through
April 2016 after obtaining approval of the KFSH&RC Re-
search Ethics Committee. All participants gave written in-
formed consent and were compensated based on the
Wage-Payment model [37] in a prorated manner.
Procedures and interventions
Ergocalciferol and cholecalciferol crystals (40,000,000 IU/g)
were purchased from AGD Nutrition, LLC (Lewisville, TX,
USA) and manufactured together with a matching placebo
by Jamjoom Pharma (Jeddah, Saudi Arabia) into green soft
gelatin capsules containing 2000, 25,000, or 50,000 IU of ei-
ther D2 or D3 or a combination of 1000 IU D2 and
1000 IU D3. The content of the capsules was confirmed by
in-house laboratory analysis (Jamjoom Pharma, accuracy
98–102%, coefficient of variation (CV) <2%) at manu-
facturing date and yearly thereafter. On average, the recov-
ered content ranged from 89.33% (D3 2000 IU) to 91.91%
(D2 25,000 IU) of the label claim and showed no trend of
decrease over study period.
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Daily doses (D2 2000 IU, D3 2000 IU, combined D2
1000 IU and D3 1000 IU, or placebo) on days 0, 1, 2, 3,
4, 7, and 14 and 2-weekly thereafter and all of the 2-
weekly (D2 25,000 IU or D3 25,000 IU) and 4-weekly
(D2 50,000 IU or D3 50,000 IU) doses were administered
by study coordinators in the research clinic after blood
samples were obtained and a standardized meal was
given. The rest of the daily doses were dispensed to par-
ticipants on a 2-weekly basis to self-administer with the
first meal of the day; compliance was emphasized and
checked by capsule counting at each research clinic visit.
Participants on daily doses were asked to skip the dose
on three Saturdays every 4 weeks so that their 4-weekly
dose totals 50,000 IU. All participants were asked to re-
port any more than habitual sun exposure or new medi-
cation/supplement. All of the seven active-treatment
groups were given the same total D dose (250,000 IU
over 140 days) and followed up for 140 days.
D2, D3, 25(OH)D2, and 25(OH)D3 serum levels were
simultaneously and blindly measured by a locally validated
reversed-phase high performance liquid chromatography
assay (HPLC) [38] on days 0, 1, 2, 3, 4, 7, and 14, and 2-
weekly thereafter. The intra-assay and inter-assay CVs
were, respectively, 4.9 and 7.5% for D2, 4.8 and 6.0% for
D3, 5.0 and 6.7% for 25(OH)D2, and 6.3 and 6.9% for
25(OH)D3. Limits of detection and quantification were,
respectively, 7.5 and 12.5 nmol/L for D2 and D3 and 5
and 12.5 nmol/L for 25(OH)D2 and 25(OH)D3 [38].
Serum calcium and phosphorous and spot urine calcium,
phosphate, and creatinine levels were determined by the
clinical laboratory at KFSH&RC on days 0 and 140.
Randomization and blinding
Blocked (block size = 8) randomization sequences, strati-
fied by body mass index (BMI ≤ 30, ≥30 kg/m2) and sex
were generated (by MMH) using an online program [39].
Assignment was concealed from potential participants
and recruiting coordinators. Participants and study coor-
dinators continued to be blinded to the content of individ-
ual assignments (D2, D3, D2 and D3, or placebo for daily
doses; D2 or D3 for 2-weekly and 4-weekly doses).
Outcome measures and analysis
The primary outcome measure was the area-under-the-
curve from day 0 to 140 (AUC140) of 25(OH)D. Prede-
termined secondary outcome measures were AUC140 of
25(OH)D2, 25(OH)D3, D2, and D3 as well as incidence
of hypercalcemia and hypercalciuria. AUC from day 0 to
7, day 0 to 14 and day 0 to 28 (AUC7, AUC14, and
AUC28) were also calculated. AUCs were analyzed using
analysis of covariance (ANCOVA). The model included
treatment group, BMI, sex, and the corresponding day
zero level. One way ANOVA was used to compare base-
line continuous variables among groups and t test was
used to compare day zero and day 140 continuous vari-
ables as well as estimated effect sizes. Analyses were per-
formed (by MMH) with IBM SPSS Statistics version 21
software. Two-tailed p-values and 95% confidence inter-
vals (CI) are reported.
Results
Two hundred seventy nine participants were random-
ized to 8 groups (D2 daily, D3 daily, combined D2/D3
daily, placebo daily, D2 2-weekly, D3 2-weekly, D2 4-
weekly, or D3 4-weekly). Ten participants withdrew
within the first week of the study and were not included
in the analysis. Two hundred twenty nine participants
completed the study and 40 (15%) lost to follow up, in-
cluding one who became pregnant (Fig. 1).
Table 1 summarizes the main characteristics per treat-
ment group of the 229 participants who completed the
study and of the entire cohort of 269 participants. There
were no statistically significant differences among the
eight groups in the listed characteristics (p = 0.32–0.90
for the 229 participants, p = 0.41–0.90 for the entire co-
hort). The 269 participants had a mean (SD) age of 33.0
(8.5) years and baseline 25(OH)D level of 39.8 (11.9)
nmol/L, and 41% were males. All were of Middle Eastern
or East Asian ethnicity.
Incompliance with self-administered daily doses as de-
termined by capsule counting was 1.6% for the D2, 1.3%
for the D3, 1.0% for the combined D2/D3, and 1.3% for
the placebo group (9,8,7, and 6 participants missed a total
of 56, 52, 40, and 46 doses, respectively). None of the par-
ticipants reported more than habitual sun exposure or
taking supplements containing vitamin D during enroll-
ment. At day 140, there was no incidence of hypercalce-
mia and mean (SD) changes in urinary calcium/creatinine
ratio and phosphate/creatinine ratio in the seven active-
treatment groups were 0.013 (0.259) and −0.183 (1.164)
mol/mol, respectively (p = 0.48 and p = 0.03, respectively).
In the placebo group, they were −0.061 (0.270) and −0.236
(1.035) mol/mol, respectively. These changes were the re-
sults of significant increase in urinary calcium and creatin-
ine levels with a mean (95% confidence interval, CI) of
0.90 mmol/L (CI, 0.34 to 1.47, p = 0.002) and 1.75 mmol/
L (CI, 0.56 to 2.94, p = 0.004), respectively, and insignifi-
cant increase in urinary phosphate of 0.37 mmol/L (−2.11
to 2.85, p = 0.77) in the 7 active treatment groups. There
were no significant changes in the corresponding parame-
ters in the placebo group (p = 0.23 to 0.95). No adverse
events were reported.
Differential effects of vitamin D regimens on 25(OH)D
level
Figure 2a to c depicts mean 25(OH)D level from day 0 to
day 140 in the eight groups. The concentration-time curve
in the placebo group was rather flat with a maximum
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mean increase in 25(OH)D level of 6.2 compared to 27.5
to 37.3 nmol/L in the seven active-treatment groups. At
day 140, the mean increase in in the active-treatment
groups was 28.6 (16.3) compared to 3.3 (11.6) nmol/L in
the placebo group. The curve flattened around day 70 in
the daily groups and around day 112 in the 2-weekly
groups. In the 4-weekly groups, it showed consistent fluc-
tuation (mean differences around 6.6 and 5.2 nmol/L in
D2 and D3 groups, respectively) with peaks and troughs,
2 weeks and 4 weeks after dosing, respectively. Interest-
ingly, there was no further increase in peak 25(OH)D level
after day 70 in the D2 4-weekly group, however, peak
Fig. 1 Participants flow chart. “Withdrew” indicates participants who did not complete the first week of the study and who were
excluded from analysis















Number 28 31 33 26 30 27 25 29
35 34 35 32 35 33 32 33
Age, year 34.4 (10.2) 34.5 (9.7) 33.1 (6.8) 31.5 (6.1) 33.5 (10.5) 32.3 (7.2) 32.6 (8.5) 32.8 (7.3)
34.7 (9.4) 33.7 (9.7) 32.8 (7.1) 31.5 (7.8) 33.4 (10.5) 33.5 (8.0) 31.4 (8.1) 32.4 (7.3)
Male, number (%) 13 (46) 13 (42) 15 (45) 12 (46) 13 (43) 11 (41) 10 (40) 13 (45)
14 (40) 14 (41) 14 (40) 14 (44) 14 (40) 13 (39) 14 (44) 13 (39)
BMI, kg/m2 24.6 (2.9) 26.1 (5.1) 26.2 (3.8) 24.1 (4.0) 24.8 (5.1) 25.3 (5.2) 25.6 (3.4) 23.9 (4.3)
25.3 (3.3) 25.9 (4.9) 26.0 (3.6) 24.3 (3.9) 24.8 (4.7) 25.4 (4.8) 25.9 (3.7) 24.1 (4.4)
Sun exposure, hour/week 2.0 (2.2) 2.2 (2.1) 2.3 (2.3) 2.3 (2.7) 3.0 (2.9) 2.5 (2.5) 3.2 (3.1) 2.3 (2.3)
2.3 (2.6) 2.2 (2.0) 2.3 (2.3) 2.7 (3.0) 2.8 (2.7) 2.4 (2.5) 3.1 (3.0) 2.2 (2.2)
Serum 25(OH)D, nmol/L 39.5 (12.2) 41.3 (10.7) 40.7 (14.5) 38.2 (10.5) 39.5 (12.5) 40.9 (12.0) 40.9 (12.2) 42.9 (10.2)
38.8 (12.1) 40.9 (10.3) 40.8 (14.5) 37.6 (10.5) 39.4 (13.0) 39.5 (12.7) 39.4 (12.3) 41.8 (10.3)
Serum 25(OH)D3, nmol/L 39.1 (12.1) 41.3 (10.7) 38.0 (12.1) 38.2 (10.5) 38.0 (11.5) 40.4 (12.2) 40.9 (12.2) 42.9(10.2)
37.2 (12.3) 40.3 (10.9) 37.8 (12.3) 37.6 (10.5) 38.2 (12.2) 38.7 (12.8) 39.4 (12.3) 41.8 (10.3)
Urinary calcium/creatinine, mol/mol 0.30 (0.19) 0.39 (0.21) 0.32 (0.22) 0.33 (0.19) 0.37 (0.26) 0.42 (0.24) 0.32 (0.20) 0.40 (0.24)
0.34 (0.23) 0.39 (0.20) 0.29 (0.17) 0.32 (0.18) 0.37 (0.26) 0.38 (0.24) 0.31 (0.20) 0.38 (0.23)
Urinary phosphate, creatinine, mol/mol 1.69 (0.80) 1.83 (1.02) 1.57 (0.91) 1.70 (0.67) 1.75 (0.76) 2.08 (1.74) 1.47 (0.78) 1.79 (1.06)
1.66 (0.83) 1.79 (1.01) 1.53 (0.78) 1.62 (0.66) 1.81 (0.74) 2.00 (1.59) 1.60 (1.18) 1.68 (1.04)
Data are means (SD), unless indicated otherwise. The first raw of each entry describes the 229 participants who completed the study; the second raw describes
the entire cohort of 269 participants. BMI, body mass index. 25(OH)D, total 25-hydroxyvitamin D. 25(OH)D3, 25-hydroxyvitamin D3
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25(OH)D level appeared to continue to increase over the
duration of the study. The curves were not grossly separ-
able in the three daily active treatment groups; however,
they were clearly separable in the two 2-weekly groups and
the two 4-weekly groups, with the groups assigned to D3
maintaining higher levels than the groups assigned to D2.
Analysis of 25(OH)D AUC140 showed significant effect
of treatment group (p < 0.001) and baseline 25(OH)D
level (p < 0.001) but not sex (p = 0.38) or BMI (p = 0.14).
Figure 2d to f shows adjusted mean (SE) 25(OH)D
AUC140 in the eight groups. All active treatment groups
had significantly higher 25(OH)D AUC140 than the pla-
cebo group (40 to 55%) with mean difference ranging
from 2530.4 nmol.d/L (CI, 1741.3 to 3319.6) in D3 daily
group to 3503.3 nmol.d/L (CI, 2711.9 to 4294.6) in D3
2-weekly group. Adjusted mean 25(OH)D AUC140 was
significantly lower in D3 daily group compared to D3 2-
weekly group (mean difference −972.8 nmol.d/L (CI,
−1751.1 to −194.6, p = 0.02) and D3 4-weekly group
(mean difference −896.4 nmol.d/L (CI, −1710.2 to −82.6,
p = 0.03). It was significantly higher in D3 2-weekly
group compared to daily D2/D3 (mean difference
852.4 nmol.d/L (CI, 85.9 to 1618.9, p = 0.03) and D2 4-
weekly group (mean difference 897.5 nmol.d/L (CI, 93.9
to 1701.1, p = 0.03). The increase in 25(OH)D level be-
tween days 0 and 140 correlated negatively with day zero
25(OH)D level (r = −0.21, p = 0.001). There was no sig-
nificant difference in day 140 serum calcium level or
urinary calcium, phosphate, or creatinine levels among
the 8 groups (p = 0.58, to 0.98, adjusted for day zero
value and sex).
Figure 3a to c depicts mean 25(OH)D level from day 0 to
day 28 in the eight groups. Adjusted mean 25(OH)D level
was not significantly different from the placebo group until
day 2 in the D2 daily (p = 0.005) and until day 3 in the D3
daily (p = 0.02) and the D2/D3 daily (p = 0.001) groups.
However, it was significantly different from day 1 in the D2
and D3 2-weekly and 4-weekly groups (p < 0.001 to 0.005).
At day 4, adjusted mean 25(OH)D level was signifi-
cantly lower in the D2 and D3 daily groups compared
to the corresponding 2-weekly groups (p = 0.02 and
0.006, respectively) and in the D2 and D3 2-weekly
groups compared to the corresponding 4-weekly
groups (p = 0.03 and p = 0.004, respectively). At day
28, adjusted mean 25(OH)D level was higher in D3
4-weekly group compared to D2 4-weekly group
A B C
D E F
Fig. 2 a, b, and c, data represent mean total 25-hydroxyvitamin D (25(OH)D) level over 140 days, in the daily, 2-weekly, and 4-weekly groups, respectively.
Squares and triangles represent D2 and D3 groups, respectively. Circles and cross marks represent combined D2/D3 and placebo groups, respectively. d, e,
and f, data represent adjusted mean (SE) 25(OH)D AUC140 in the daily, 2-weekly, and 4-weekly groups, respectively
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(mean difference 6.4 nmol/L (CI, 1.5 to 11.3, p =
0.01)) and in D3 2-weekly group compared to D2 2-
weekly group (mean difference 4.5 nmol/L (CI, −0.4
to 9.5, p = 0.07)). On the other hand, 25(OH)D level
was significantly higher in D2 daily group compared
to D3 daily group (mean difference 6.2 nmol/L (CI,
1.4 to 11.0, p = 0.01)).
Analysis of 25(OH)D AUC7, AUC14, and AUC28
showed significant effect of treatment group (p < 0.001),
baseline 25(OH)D level (p < 0.001), and BMI (p = 0.002
to 0.004) but not sex (p = 0.55 to 0.85). Figure 3d to f de-
picts adjusted mean (SE) 25(OH)D AUC7, AUC14, and
AUC28 in the eight groups. Adjusted mean 25(OH)D
AUC7 was significantly (p < 0.001) higher in the active-
treatment groups compared to the placebo group (mean
difference ranging from 36.0 nmol.d/L (CI, 13.2 to 58.7)
to 126.9 nmol.d/L (CI, 104.0 to 149.7). In the D3 treated
groups, adjusted means of 25(OH)D AUC7, AUC14, and
AU28 were significantly lower in the daily group com-
pared to the 2-weekly (p = 0.005 to 0.04) and the 4-
weekly (p < 0.001) groups. In contrast, in the D2 treated
groups, although adjusted mean 25(OH)D AUC7 was
significantly lower in the daily group compared to the 2-
weekly and 4-weekly groups (p = 0.02 and p < 0.001,
respectively), adjusted mean 25(OH)D AUC14 was sig-
nificantly lower only in the daily group compared to the
4-weekly group, and adjusted mean 25(OH)D AUC28
was not significantly different in the daily group com-
pared to the 2-weekly or 4-weekly groups (p = 0.42 and
p = 0.36, respectively). There was significant negative
correlation between 25(OH)D AUC7, AUC14, and AUC28
and BMI in the D2 treated groups (r = −0.25, p = 0.01 for
all) but not in D3 treated groups (r = −0.10, p = 0.32 to
0.36). In summary, the data suggest that in the long term
(20 weeks), D3 2-weekly followed by D3 4-weekly and
D2 daily regimens may be superior in raising 25(OH)D
level. However, in the first few weeks of treatment,
the 4-weekly regimens followed by 2-weekly regimens
appear to be superior to all daily regimens. Further,
D3 2-weekly and 4-weekly regimens appear to be
consistently superior to the corresponding D2 regi-
mens, and D2 daily regimen appears to be consist-
ently superior to D3 daily regimen. Finally, the
increase in 25(OH)D level appears to be inversely re-
lated to BMI (mainly short term after D2 treatment)




Fig. 3 a, b, and c, data represent mean total 25-hydroxyvitamin D (25(OH)D) level over the first 28 days of the study, in the daily, 2-weekly, and
4-weekly groups, respectively. Squares and triangles represent D2 and D3 groups, respectively. Circles and cross marks represent combined D2/D3
and placebo groups, respectively. d, e, and f, data represent adjusted mean (SE) 25(OH)D AUC7 (open bars), AUC14 (dotted bars), and AUC28 (closed
bars) in the daily, 2-weekly, and 4-weekly groups, respectively
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Differential effects of vitamin D regimens on 25(OH)D2
and 25(OH)D3 levels
Figure 4a shows mean 25(OH)D2 level from day 0 to day
140 in the eight groups. Analysis of 25(OH)D2 AUC140
showed significant effect of treatment group (p < 0.001)
and baseline 25(OH)D2 level (p < 0.001) but not BMI (p =
0.18) or sex (p = 0.28). Figure 4b depicts adjusted mean
(SE) 25(OH)D2 AUC140 in the three D2 treated groups.
Adjusted mean 25(OH)D2 AUC140 was significantly
higher (17 and 20%) in D2 daily group compared to D2 2-
weekly group (mean difference 881.5 nmol.d/L (CI, 257.0
to 1506.1, p = 0.006)) and D2 4-weekly group (mean differ-
ence 1029.2 nmol.d/L (CI, 410.5 to 1648.0, p = 0.001)),
with no significant difference between the 2-weekly and 4-
weekly groups (p = 0.65). In contrast, adjusted mean
25(OH)D2 AUC7 and AUC14 were significantly lower in
the D2 daily group compared to D2 2-weekly group (mean
difference −42.0 nmol.d/L (CI, −56.5 to −27.6, p < 0.001)
and −38.5 nmol.d/L (CI, −70.6 to −6.5, p = 0.02), res-
pectively) and to D2 4-weekly group (mean difference
−91.4 nmol.d/L (CI, −105.7 t0 -77.2, p < 0.001) and
−136.9 nmol.d/L (CI, −168.0 to −105.8, p < 0.001), respect-
ively). Further, 25(OH)D2 AUC7, AUC14, and AUC28 were
significantly higher in D2 4-weekly group compared to 2-
weekly group (p < 0.001, p < 0.001, and p = 0.01, respect-
ively). Furthermore, 25(OH)D2 AUC7, AUC14, and AUC28
were significantly associated with BMI (p < 0.001, p <
0.001, p = 0.001, respectively) and sex (p = 0.003, p = 0.02,
p = 0.046, respectively).
Figure 4c shows mean 25(OH)D3 level from day 0
to day 140 in the eight groups. Analysis of 25(OH)D3
AUC140 showed significant effect of treatment group
(p < 0.001), baseline 25(OH)D3 level (p < 0.001), but not
sex or BMI (p = 0.55). Figure 4d depicts adjusted mean
(SE) 25(OH)D3 AUC140 in the three D3 treated groups.
Adjusted mean 25(OH)D3 AUC140 was significantly lower
in the D3 daily group compared to D3 2-weekly group
(mean difference −1002.2 nmol.d/L (CI, −1641.4 to
−363.0, p = 0.002)) and D3 4-weekly group (mean differ-
ence −910.5 nmol.d/L (CI, −1577.4 to −243.5, p = 0.008)),
with no significant difference between the 2-weekly and 4-





Fig. 4 a and c, data represent mean 25-hydroxyvitamin D2 (25(OH)D2) and 25(OH)D3 levels, respectively, over 140 days. Squares and triangles
represent D2 and D3 groups, respectively. Circles and cross marks represent combined D2/D3 and placebo groups, respectively. Solid, doted, and
interrupted lines represent daily, 2-weekly, and 4-weekly groups, respectively. b and d, data represent adjusted mean (SE) 25(OH)D2 AUC140 in the
D2 treated groups and 25(OH)D3 AUC140 in the D3 treated groups, respectively
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on; adjusted mean 25(OH)D3 AUC7, AUC14, and AUC28
were significantly lower in D3 daily group compared to
D3 2-weekly group (p < 0.001, p = 0.003, and p = 0.01, re-
spectively) and D3 4-weekly group (p < 0.001, p < 0.001,
and p < 0.001, respectively), and adjusted mean
25(OH)D3 AUC7, AUC14, and AUC28 were signifi-
cantly higher in the D3 4-weekly group compared to
2-weekly group (p < 0.001, p = 0.001, and p = 0.046,
respectively). Further, 25(OH)D3 AUC7, AUC14, and
AUC28 were not associated with BMI (p = 0.32 to 0.61) or
sex (p = 0.18 to 0.34).
Interestingly, in the D2/D3 group, 25(OH)D2 level in-
creased to about one third to one half the levels in the
three D2 treated groups (Fig. 4a, however, 25(OH)D3
did not increase (Fig. 4c. Further, in the three D2 treated
groups, 25(OH)D3 level progressively and consistently
decreased over the course of the study (Fig. 4c. It de-
clined from a mean of 39.2 nmol/L at day 0 to 33.0,
31.6, 28.6, and 22.9 at days 7, 14, 28, and 140, respect-
ively. To further explore the effect of D2 treatment on
25(OH)D3 level, we examined the correlation between
the changes (day 140 minus day 0) in 25(OH)D3 level
and 25(OH)D2 level in the three D2 treated groups. As
shown in Fig. 5a, there was significant negative correl-
ation (r = −0.48, p < 0.001). However, the change in
25(OH)D3 level also correlated negatively with day zero
25(OH)D3 level (r = −0.58, p < 0.001) and with day 140
25(OH)D levels (r = −0.32, p = 0.003). Of note, in one
participant who started with measurable 25(OH)D2 level
and received D3 2-weekly, 25(OH)D2 level decreased by
16.4 nmol/L between days 0 and 140 (Fig. 5b). In compari-
son, the mean decrease in 25(OH)D3 level in the three D2
treated groups was 16.4 nmol/L (CI, 14.0 to 18.7, p <
0.001), suggesting that D3 treatment may also induce a
decline in 25(OH)D2 level of the same magnitude.
Differential effects of vitamin D regimens on D2 and D3
levels
At day zero, D2 and D3 levels were undetectable or only
traceable in all the 8 groups. D2 and D3 levels were
quantifiable only during the first week of treatment in
the 2-weekly and 4-weekly groups. The following ana-
lysis is therefore restricted to the 2-weekly and 4-weekly
groups. D2 and D3 concentration-time curves in the 2-
weekly and 4-weekly groups are shown in Fig. 6a and b.
As expected mean D2 and D3 levels were twice as high in
the 4-weekly groups compared to the 2-weekly groups.
Interestingly, mean D3 levels in the D3 treated groups
were higher than mean D2 levels in the corresponding D2
treated groups (Fig. 6a). In the D2 treated groups, analysis
of D2 AUC7 showed significant effect of treatment group
(p < 0.001), sex (p = 0.01), and BMI (p = 0.001). In the D3
treated groups, analysis of D3 AUC7 showed significant ef-
fect of treatment group (p < 0.001), sex (p < 0.001), but not
BMI (p = 0.06). Adjusted mean D2 AUC7 was 200% higher
in the 4-weekly group compared to 2-weekly group with a
mean difference of 100.2 nmol.d/L (CI, 62.3 to 138.0, p <
0.001), and adjusted mean D3 AUC7 was 90% higher in
the 4-weekly group compared to 2-weekly group with a
mean difference of 155.7 nmol.d/L (CI, 109.8 to 201.6, p <
0.001). Adjusted mean D3 AUC7 was 243% higher than
D2 AUC7 in the 2-weekly groups (mean (SE) 172.2 (16.1)
vs 50.2 (13.5) nmol.d/L) with a mean difference of
122.0 nmol.d/L (CI, 79.8 to 164.1, p < 0.001) and 118%
higher in the 4-weekly groups (mean (SE) 327.9 (16.4)
vs 150.4 (13.4) nmol.d/L) with a mean difference of
177.5 nmol.d/L (CI, 135.3 to 219.8, p < 0.001). Fig-
ure 6b shows that mean D2 levels in D2 treated
groups and mean D3 levels in D3 treated groups are
(64 and 55%, respectiv1ely) higher in females than
males. Adjusted mean difference in AUC7 was
48.5 nmol.d/L (CI, 10.3 to 86.6, p = 0.01) for D2 and
107.7 nmol.d/L (CI, 61.5 to 154.0, p < 0.001) for D3.
Interestingly, BMI correlated significantly with D2 AUC7
(r = −0.27, p = 0.03) but not D3 AUC7 (r = −0.05, p = 0.67).
A
B
Fig. 5 a, Data show correlation between the changes (day 140 - day
0) in 25(OH)D3 levels and 25(OH)D2 levels in the three D2 treated
groups (r = −0.48, p < 0.001). b, levels of D3 (open triangles), 25(OH)D2
(closed squares), and 25(OH)D3 (closed triangles) are depicted over
140 days in one participant from the D3 2-weekly group who
happened to have measurable 25(OH)D2 at day zero
Hammami and Yusuf BMC Endocrine Disorders  (2017) 17:12 Page 8 of 14
To explore the reasons for the differential effects of
sex and D-type on D2 and D3 levels, we examined
25(OH)D2 levels in the D2 treated groups and
25(OH)D3 levels in the D3 treated groups after subtract-
ing the corresponding baseline levels. As shown in
Fig. 6c, mean 25(OH)D2 levels in the D2 treated groups
were higher than mean 25(OH)D3 levels in the corre-
sponding D3 treated groups. Adjusted mean (SE)
25(OH)D2 AUC7 was 39% higher than adjusted mean
25(OH)D3 AUC7 in the 2-weekly groups (mean (SE)
107.9 (8.9) vs 77.4 (7.7) nmol.d/L) with a mean differ-
ence of 30.5 nmol.d/L (CI, 7.2 to 53.9, p = 0.01) and 31%
higher in the 4-weekly groups (mean (SE) 163.2 (8.9) vs
124.5 (8.0) nmol.d/L) with a mean difference of
38.7 nmol.d/L (CI, 14.8 to 62.5, p < 0.002). This together
with higher D3 levels in the D3 treated groups compared
to D2 levels in the D2 treated groups as shown above,
suggest faster 25-hydroxylation of D2 compared to D3.
However, faster 25-hydroxylation could not account for
all the observed difference between D2 and D3 levels.
As shown in Fig. 6d, mean 25(OH)D2 levels in the D2
treated groups and mean 25(OH)D3 levels in the D3
treated groups were higher in females compared to
males. Adjusted mean (SE) 25(OH)D2 AUC7 was 28%
higher in females compared to males (152.2 (8.1) vs
118.9 (9.6) nmol.d/L) with a mean difference of
33.4 nmol.d/L (CI, 8.2 to 58.5, p = 0.01). Adjusted mean
(SE) 25(OH)D3 AUC7 was 13% higher in females
compared to males (106.9 (7.2) vs 95.0 (8.6) nmol.d/L)
with a mean difference of 11.9 nmol.d/L (CI, −10.8 to
34.6, p = 0.3). In retrospect, the significant difference be-
tween females and males in 25(OH)D2 levels in the 2-
weekly and 4-weekly groups was found to be present at
day 140; mean (SE) 25(OH)D2 AUC140 was 5509.0
(274.2) vs 4526.5 (313.5) nmol.d/L with a mean differ-
ence of 982.5 nmol.d/L (CI, 137.6 to 1827.3, p = 0.02).
This together with higher D2 levels in D2 treated
groups and D3 levels in the D3 treated groups in fe-
males compared to males as shown above, suggest
higher D2 and D3 circulation availability in females com-
pared to males. Finally, BMI correlated significantly with
25(OH)D2 AUC 7 (r = −0.34, p = 0.006) but not
25(OH)D3 AUC7 (r = −0.11, p = 0.38).
Discussion
The primary aim of this randomized placebo-controlled,
partially-blinded study on 269 healthy adults with mean
25(OH)D of 39.8 (11.9) nmol/L was to evaluate the rela-
tive efficacy of equi-unit D2 and D3 oral supplements
given daily, 2-weekly, or 4-weekly in raising 25(OH)D
level over 20 weeks. Predetermined secondary aims in-
cluded comparing D2, D3, 25(OH)D2, and 25(OH)D3
levels. The primary outcome measure was adjusted area-
under-the-curve between days 0 and 140 (AUC140). The
main results were: 1) in the long term (20 weeks), the
D3 2-weekly followed by D3 4-weekly and D2 daily
A B
C D
Fig. 6 a, data represent mean D3 (closed triangles) and D2 (closed squares) levels in the 4-weekly (interrupted lines) and 2-weekly (solid lines)
groups. b, data represent mean D3 (open triangles) and D2 (open squares) levels in females (interrupted line) and males (solid lines) in the 2-weekly
and 4-weekly groups. C, data represent mean 25(OH)D3 (closed triangles) and 25(OH)D2 (closed squares) levels in the 4-weekly (interrupted lines)
and 2-weekly (solid lines) groups after subtracting day zero levels. D, data represent mean 25(OH)D3 (open triangles) and 25(OH)D2 (open squares)
levels in females (interrupted lines) and males (solid lines) in the 2-weekly and 4-weekly groups after subtracting day zero levels
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regimens were superior in raising 25(OH)D levels. In the
first few weeks of treatment, however, the 4-weekly
followed by 2-weekly regimens were superior to all daily
regimens. 2) D3 2-weekly and 4-weekly regimens were
consistently superior to the corresponding D2 regimens;
however, D2 daily regimen was consistently superior to
D3 daily regimen. 3) 25(OH)D2 level was significantly
higher in the daily compared to the 2-weekly and 4-
weekly D2-treated groups, whereas, 25(OH)D3 level was
lower in the daily compared to the 2-weekly and 4-
weekly D3-treated groups 4) The increase in 25(OH)D
level was inversely related to baseline level, however, its
inverse relation to BMI appeared to be D-type and time
dependent (mainly short time after D2 treatment). 5)
Daily, 2-weekly, and 4-weekly D2 regimens were associ-
ated with a similar and significant decrease in
25(OH)D3 level that correlated with the increase in
25(OH)D2 level and baseline 25(OH)D level, in one par-
ticipant with measurable baseline 25(OH)D2 level, D3
caused a similar decrease in 25(OH)D2 level, while in
the D2/D3-treated group, 25(OH)D3 level didn’t in-
crease. 6) The increases in D3 level in the 2-weekly and
4-weekly D3 treated groups were higher than the in-
creases in D2 level in the corresponding D2 treated
groups, the opposite was true for 25(OH)D2 and
25(OH)D3 levels. 7) Females had higher increases in D3,
D2, 25(OH)D2, and 25(OH)D3 levels than males. 8) D
treatment was associated with significant increases in
urinary calcium and creatinine levels but not calcium/
creatinine ratio.
All of the seven D supplement regimens in our study
significantly increased 25(OH)D. At day 140, mean in-
crease was 3.3 nmol/L in the placebo group and
28.6 nmol/L in the active-treatment groups. Although
comparison is difficult because the dose–response curve
is curvilinear, with an average of 1786 IU/day, this trans-
lates into an increase of about 16 nmol/L per 1000 IU,
which is consistent with previous observations [8, 21, 26,
27, 36, 40]. In men with baseline 25(OH)D of 70 nmol/
L, it was estimated that the increase in 25(OH)D level is
about 17.5 nmol/L per 1000 IU daily D3 dose [40]. A re-
view of recordings of 17,614 healthy adults participating
in a preventive health program found an average in-
crease of 12 nmol/L per 1000 IU for daily dosing interval
of 0 to 1000 IU [21]. In a multicenter, retrospective data
extraction study, an average daily dose of 2700 IU D3 in-
creased 25(OH)D by 11.8 nmol/L per 1000 IU [27]. It is
to be noted that the recovered content of the capsules in
our study was about 90% of the label claim and that
compliance with study medication was 98.4 to 100%. In
our study, the increase in 25(OH)D level plateaued
around days 70 and 112 in the daily and 2-weekly
groups, respectively. Time to plateau ranged from
5 weeks to five months in previous studies [40, 41]. Due
to our relatively frequent sampling, we were able to ob-
serve clear fluctuations in 25(OH)D levels when mea-
sured 2 weeks and 4 weeks after dosing, which may have
clinical implication in term of monitoring response to
therapy. Interestingly, the fluctuations were more pro-
nounced with D2 dosing, consistent with shorter half life
of 25(OH)D2 [4, 7, 42].
Our finding that D3 is superior to D2 in raising
25(OH)D level when given 2-weekly or 4-weekly is con-
sistent with the published literature. The superiority of
D3 was seen in studies that used 50,000 IU daily [5] or
weekly, [4] a bolus of 300,000 [42] or 50,000 IU, [7] and
a bolus of 10,000,000 IU in cows, [43] but not in studies
that used 400 IU daily, [8, 9] 1000 IU daily, [29, 36] or
2000 IU daily [10]. Nevertheless, it was also reported
with daily doses of 4000 IU for 14 days [11]. A 2012
meta-analysis found that D3 is more potent than D2,
interestingly the difference was significant in the 4 RCTs
(48 patients) that used bolus oral or intramuscular doses
but not in the 6 RCTs (146 patients) that used daily sup-
plements [24]. The interaction between D-type and dos-
ing schedule was clearly shown in this study; while daily
D3 was less efficient than 2-weekly and 4-weekly D3 in
raising 25(OHD3, daily D2 was superior to 2-weekly and
4-weekly D2 in raising 25(OH)D2 levels. It is to be noted
that the formulation of the capsules in our study was
based on the common unitage that 1 IU equals 25 ng
crystalline D2 or D3. Since the molecular weights of D2
and D3 are 384 and 396, respectively, 25 ng D3 would
be equivalent to 25.78 ng, [28] thus the potency of D2
may have been underestimated by about 3% if one con-
siders molar equivalence rather than weight equivalence
in determining potency in IUs. Our results suggest that
for long term results, D2 is best given daily while D3 is
best given 2-weekly. However, the 4-weekly followed by
the 2-weekly (D2 or D3) regimens are clearly superior in
in rapidly raising 25(OH)D levels.
We observed consistent decrease in 25(OH)D3 levels
in D2 treated groups. This was observed in most [8, 33,
44] but not all [29] previous studies that fractionated
25(OH)D levels. In a meta-analysis of RCTs on the effect
of UV-exposed mushrooms consumption, the increase
in 25(OH)D2 level was associate with a decrease in
25(OH)D3 level [35]. Further, 1000 IU D3 daily for
11 week did not change 1,25(OH)2D3 level, while
1000 IU D2 daily increased 1,25(OH)2D2 level by 7.4 pg/
ml and decreased 1,25(OH)2D3 level by 9.9 pg/ml [36].
A similar decrease in 1,25(OH)2D3 was seen in response
to 4000 IU D2 daily for 8 weeks [44]. Several observa-
tions from our study may shed light on the mecha-
nism(s) underlying these observations. We found that
the D2-induced decrease in 25(OH)D3 level was similar
in the daily, 2-weekly, and 4-weekly groups, that it was
correlated with the increase in 25(OH)D2 level, baseline
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25(OH)D level, and day 140 25(OH)D level, that there
was no change in 25(OH)D3 level in the group treated
with a combination of D2 and D3, and that when
25(OH)D2 level is measurable (one case), D3 treatment
resulted in a similar decrease in 25(OH)D2 level. These
observations suggest that the D2-induced decrease in
25(OH)D3 level may more related to the resulting
25(OH)D level rather than being specific to D2 treat-
ment. In fact, in one study, 400 and 1000 IU D3 daily
for one year resulted in an increase in 25(OH)D3 level
with a concomitant decrease in 25(OH)D2 level [34].
Interestingly, in a crossover study on high-yielding dairy
cows, pre-administration of 10,000,000 IU of D3 signifi-
cantly reduced 25(OH)D2 response to 10,000,000 IU of
D2 [43]. It may be that there is a regulatory mechanism
that increases the disposal of 25(OH)D in response to
increases in its level [20] and that it has been observed
with D2 treatment mainly because study participants
commonly don’t have measurable 25(OH)D2 levels.
Since there was essentially no change in 25(OH)D3 level
in the group that received combination of 1000 IU D2
and 1000 IU D3, it appears that, in a setting similar to
our study (baseline 25(OH)D level around 40 nmol/L
and average dose of 1800 IU daily), an amount of
25(OH)D that can be produced by 1000 IU intake is dis-
posed daily. If such a mechanism really exists it can be
exploited in defining normal 25(OH)D levels.
Consistent with the above interpretation and with pre-
vious studies, [9, 11–16, 26, 35] we found significant
negative correlation between baseline 25(OH)D level
and response to treatment. A recent review found that
17 out of 20 studies documented such correlation (3
studies had inadequate sample size and variation in
baseline level), which may explain up to 20% of response
variation [13]. A recent systematic review of studies that
used modest daily doses of D3 (200 to 800 IU), also
found negative correlation, albeit not significant [26].
The negative correlation together with the non-linear re-
sponse in 25(OH)D level to increasing doses of D [6, 16,
20, 21] again suggest a regulatory step mechanism [20].
In our study, the significant negative correlation between
baseline and increment 25(OH)D level was first seen at
day 28 (when 25(OH)D level was 59.1 (14.7) nmol/L),
suggesting a threshold effect. Interestingly, pooling data of
3 RCTs, subjects with single nucleotide polymorphisms
(linked to D binding proteins and 25-hydroxylase) that are
associated with the lowest baseline 25(OH)D level had the
smallest increase in 25(OH)D level (32). Thus in some
subjects, low baseline 25(OH)D level may reflect a
genetic potential rather than lifestyle influence and
may be associated with lower rather than higher in-
crement in 25(OH)D level.
Higher BMI/body fat percentage was associated with
smaller response to D supplement in several studies
[12–14, 18–21, 45]. BMI may be a better predictor than
absolute weight [21] and was suggested as the most
powerful response predictor to D supplement [19]. Up
to 34.5% of response variation may be related to BMI,
more apparently with higher D doses [13]. In a large
retrospective study, mean increases in 25(OH)D level
were 28.7, 23.6, and 20.1 nmol/L with BMI <25, 25–29,
or ≥ 30 kg/m2, respectively [18]. Nevertheless, not all
studies showed such negative association [13]. This may
be due to the fact that higher BMI is also associated with
baseline lower 25(OH)D levels, [17, 45] which is itself
positively associated with response to D supplement. In
our study, BMI was a significant response predictor to
D2 but not D3 and only during the first 4 weeks of treat-
ment, suggesting two additional potential modifiers of
the relationship between BMI and 25(OH)D response to
D supplement, D-type and time of assessment. The
mechanisms underlying the association between BMI
and response to D supplement are not clear. It was sug-
gested that D and 25(OH)D may be trapped in access
adipose tissue, as 25(OH)D is released with weight loss
1–6 months following bariatric surgery [46, 47]. How-
ever, total body fat storage may account for only 17% of
the administered dose (extrapolated from subcutaneous
fat), [4] and D and 25(OH)D may be also deposited in
liver, muscle, and skin as shown in animal studies, sug-
gesting that volume dilution may play a role [20]. The
relatively lower affinity of D binding protein to D2 and
25(OH)D2 [24, 28] makes them more accessible to
extra-vascular tissues, which may explain our finding.
We found that the increase in D3 level was 2–3 fold
higher than the increase in D2 level (in the 2-weekly and
4-weekly treated groups). Few studies examined D2 and
D3 after D2 and D3 supplementation [4, 43]. After simi-
lar doses of D2 and D3 (50,000 IU weekly for 12 weeks),
subcutaneous fat D3 storage was 2 times higher than D2
storage [4]. Equivalent pharmaceutical doses of D3 and
D2 in cows increased D3 level more than D2 level, re-
spectively [43]. The difference may be related to the dif-
ferent structure of D2 and D3 side chains, theoretically
causing differential absorption, binding to D binding
proteins, inactivation by 24-hydroxylation, or activation
by 25-hydroxylation. Absorption is not likely to be in-
volved as studies of tritium-labeled D2 and D3 in
healthy subjects found similar recoveries after oral dos-
ing, however, D binding protein has double association
constant to D3 compared to D2, and in vitro, mitochon-
drial 25-hydroxylase is 5 times faster for D3 compared
to D2 [11, 24, 28]. It is to be noted that most of the
ingested D is not converted to 25(OH)D; an RCT found
that oral 25(OH)D3 is 4–5 more potent than D3 in rais-
ing 25(OH)D3 levels, [41] Interestingly, in our study,
25(OH)D2 levels were higher than 25(OH)D3 levels,
suggesting that the lower D2 levels were due, at least in
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part, to higher D2 accessibility to the 25-hydroxylase en-
zyme because of lower affinity to D binding proteins. It
is of note that the combination of D3 AUC7 and
25(OH)D3 AUC7 was about 50% higher than the com-
bination of D2 AUC7 and 25(OH)D2 AUC7; indicating
that a mechanism other than faster 25-hydroxylation
(such as higher accessibility of D2 and 25(OH)D2 to
extra-vascular tissues and faster degradation) is also in-
volved. These mechanisms may apply only for schedules
using high doses as 25(OH)D AUC140 was higher in D2
daily than D3 daily treatment.
The higher levels of D3 compared to D2 may have im-
portant implication regardless of their impact on serum
25(OH)D level. Because of lower affinity to D binding pro-
tein, D2 and D3 have more cellular accessibility than
25(OH)D2 and 25(OH)D3 (except for the kidney, parathy-
roid gland, and placenta, where the megalin-cubulin sys-
tem is expressed) and may have important physiological
roles in breast milk and as substrates for many tissues [2].
We found that females had significantly larger (60, 55,
28%) adjusted AUC7 than males for D2, D3, and
25(OH)D2 levels (and larger 13%,but not significant in-
crease in 25(OH)D3 level). Females also had significantly
22% larger adjusted 25(OH)D2 AUC140.
The results suggest about 49% better bioavailability of
both D2 and D3 in females. Sex effect on response to D
supplement has not been directly studied before. How-
ever, it is of note that D binding proteins are higher in fe-
males than males, in premenopausal women compared to
postmenopausal women, in pregnant women, in women
on oral contraceptives, [22] and in postmenopausal
women hormone replacement therapy [23]. Further, estro-
gens increase hepatic 25-hydroxylation of D and the im-
pact of D binding protein on response to D treatment
may be partly D-type dependent [13]. The observed sex
differences may be related to higher D binding protein
and faster 25-hydroxyaltion in females; although a sex dif-
ference in D absorption rate cannot be excluded. It is also
possible that higher body fat and lower baseline 25(OH)D
levels in females may play a role.
In agreement with previous studies using even higher
doses of D, [6, 48, 49] none of our participants devel-
oped hypercalcemia or hypercalciuria. In fact, the in-
crease in urinary calcium/creatinine ratio was not
significant. Nevertheless, the calcium/creatinine ratio
may be misleading as there was significant increase in
both calcium and creatinine urinary excretion. An in-
crease in creatinine generation and urinary excretion has
been described in patients with chronic kidney disease
treated with vitamin D receptor activator, paricacitol
[50]. The increase in creatinine excretion associated
with D treatment casts doubt on the usefulness of ra-
tios that include urinary creatinine (such as albumin/
creatinine and calcium/creatinine) in evaluating the
effect of D treatment on kidney function [51, 52] or D
intoxication [53].
The strengths of this study include using repeated mea-
surements, having a placebo arm, and ability to study sev-
eral active-treatment regimens simultaneously, which
enabled observing small changes and uncovering mechan-
istic insights. They also include effective randomization
and concealment, partial blinding, frequent follow up to
strengthen and verify compliance and verification of D
capsule content across the study period.
Limitations
The interpretation of the results of this study may be lim-
ited by its sample size, 15% follow up loss, lower compli-
ance with daily compared to 2-weekly and 4-weekly
regimens, capsule content that is lower than label claim,
and capsule formulation based on weight equipotency of
D2 and D3. The rate of follow up loss was similar across
the groups, the characteristics of participants who com-
pleted the study were similar to those of the entire cohort,
incompliance rate was 1 to 1.6% in the daily groups, and
the discrepancy between capsule content and label claim
was similar across the capsules; thus these factors would
not be expected to affect the main findings of the study. Al-
though the incompliance rate was low, it was measured by
capsule count, which may not be reliable. Thus the lower
dose–response observed with daily D3 treatment compared
to 2-weekly and 4-weekly D3 treatments could be explained
at least in part by incompliance. However, such explanation
is not likely given our observation that the dose–response
was higher with daily D2 treatment compared to 2-weekly
and 4-weekly D2 treatments and the fact that assignment
to daily D2 or D3 treatment was random and blinded. The
lower capsule content implies that the observed increments
in D and 25(OH)D levels may have been up to 10% higher.
Further, the fact that the molecular weight of D2 is about
3% higher compared to D3 indicates that our study may
have underestimated response to D2 treatment. Neverthe-
less, such difference would not be expected to change the
conclusions of the study. Further, the strength (in terms of
IU) of most currently available D supplements is based on
the assumption of weight rather than molar equipotency of
D2 and D3. Another limitation of the study is that our find-
ings may not be generalizable to lower or higher doses of
vitamin D, or to subjects with different baseline 25 (OH)D
levels, with different demographics, or with co-morbidities.
Also, since the study was exploratory in nature, we have
conducted multiple comparisons (including ad hoc com-
parisons), which would increase the rate of type 1 error.
Further, the study examined surrogate endpoints (vitamin
D and hydroxyvitamin D levels) rather than clinical end-
points. Finally, due to our assay sensitivity, we were not able
to measure D2 and D3 levels in the daily treated groups.
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Conclusions
We conclude that: 1) the effects of D2 and D3 supple-
ments on 25(OH)D level may be dosing-schedule, time
and sex dependent. In the long term, D2 appears to be
most effective when given daily and D3 appears to be
most effective when given 2-weekly. Further, females ap-
pear to mount larger 25(OH)D response to D2 than males.
2) The D2-associated reduction in 25(OH)D3 level ap-
pears to be related to the increase in 25(OH)D level rather
than being D2-specific, as it is related to baseline
25(OH)D level and D3 treatment may be also associated
with a reduction in 25(OH)D2 level. This together with
the well known association between baseline 25(OH)D
level and response to D treatment suggest a regulatory
mechanism that may be exploited in fine tuning determin-
ation of normal 25(OH)D level. 3) D2 appears to be 25-
hydroxylated faster than D3. 4) The association between
BMI and response to D supplement may be more pro-
nounced with D2 and during the first few weeks of treat-
ment. 5) D2 and D3 level in response to treatment are
higher in females compared to males. 6) D treatment is as-
sociated with an increase in urinary creatinine level, which
makes assessment of D effect using ratios that include cre-
atinine misleading.
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